Sex- and Gender-specific Observations and Implications for COVID-19 by Walter, Lauren A. & McGregor, Alyson J.
UC Irvine
Western Journal of Emergency Medicine: Integrating Emergency 
Care with Population Health
Title
Sex- and Gender-specific Observations and Implications for COVID-19
Permalink
https://escholarship.org/uc/item/76f9p924
Journal
Western Journal of Emergency Medicine: Integrating Emergency Care with Population 
Health, 21(3)
ISSN
1936-900X
Authors
Walter, Lauren A.
McGregor, Alyson J.
Publication Date
2020
DOI
10.5811/westjem.2020.4.47536
License
https://creativecommons.org/licenses/by/4.0/ 4.0
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Volume 21, no. 3: May 2020 507 Western Journal of Emergency Medicine
Editorial
 
Sex- and Gender-specific Observations and Implications 
for COVID-19
 
Lauren A. Walter, MD*†
Alyson J. McGregor, MD, MA*†
 
Section Editor: Mark I. Langdorf, MD, MHPE   
Submission history: Submitted April 2, 2020; Accepted April 3, 2020 
Electronically published April 10, 2020         
Full text available through open access at http://escholarship.org/uc/uciem_westjem   
DOI: 10.5811/westjem.2020.4.47536
[West J Emerg Med. 2020;21(3)507-509.]
University of Alabama at Birmingham, Department of Emergency Medicine, Birmingham, 
Alabama
Warren Alpert Medical School of Brown University, Department of Emergency Medicine, 
Providence, Rhode Island
*
†
Disclaimer: Due to the rapidly evolving nature of this outbreak, 
and in the interests of rapid dissemination of reliable, actionable 
information, this paper went through expedited peer review. 
Additionally, information should be considered current only at the 
time of publication and may evolve as the science develops. On 
February 11, 2020, the World Health Organization renamed the 
virus COVID-19.
This is a critical time for medicine. As we observe 
the exponential rise in the number of individuals in the 
United States (US) who are infected with COVID-19, 
we try to prepare. Those in the front lines are trying to 
protect themselves and their patients with the daily ration 
of personal protective equipment and ventilation assistive 
equipment. Many individuals are racing against time to 
develop the needed novel treatments and vaccines. Public 
health officials work with what little information is known 
in order to make effective recommendations for prevention. 
However, at this pivotal time in history where every detail 
obtained by US health officials could be lifesaving, we are 
leaving out vital information.
Descriptive and observational data from Wuhan, China, 
note that the majority (51%-66.7%) of affected patients have 
been male. In addition, male sex was an independent risk 
factor associated with refractory disease and death (2.8% 
death rate for men vs 1.7% for female).1,2 Currently, men 
represent 58% of COVID-19 infected patients in Italy and 
70% of COVID-related deaths.3 As coronavirus cases and 
deaths in the US continue to soar, sex-specific, comprehensive 
data with regard to US patients is not yet available. 
Sex- and gender-based medicine (SGBM) incorporates 
how biological sex and the sociocultural aspects 
of gender affect health and illness. It acknowledges the 
interrelationship between sex and gender on health outcomes 
and promotes consideration of this variable in both research 
and clinical practice. SGBM has demonstrated significant 
evidence-based impact on cardiovascular disease, stroke, 
sports medicine, and pain management, just to name a few
Sex and gender differences have been observed in 
infectious diseases previously. On a broad and critical 
scale, Nasir et al demonstrated that males with all-cause 
infectious sepsis have a 70% greater mortality than their 
female counterparts. Likewise, respiratory infection-specific 
epidemiological data from recent SARS (2003) and MERS 
(2012) outbreaks demonstrated a significantly higher case 
fatality rate in males as compared to females, 21.9% vs 
13.2%.4,5
Sex-specific Factors
Is the biological male more susceptible to an increased 
severity of infection? Or does the biological woman have 
natural protection against these viruses? In a 2017 BMJ 
article, Dr. Kyle Sue demonstrated the effect of sex hormones, 
estrogen and testosterone, on immune system response 
and engagement, resulting in a less robust immunologic 
response in males and subsequent increased morbidity and 
mortality from viral respiratory illnesses.6 In addition, the X 
chromosome carries the largest number of immune-related 
genes in the human genome, perhaps also contributing to 
female’s superior immune response (as well as a female 
preponderance in autoimmune diseases).7
Angiotensin-converting enzyme 2 (ACE2) and its role 
in viral transmission and associated morbidity has also been 
a topic of recent COVID-19 associated discussion. ACE2 
receptors on pulmonary endothelium serve as a main entry 
point for coronavirus. Several previous animal models 
have demonstrated increased ACE2 activity in the male or 
ovariectomized model, suggesting a sex hormone influence.8 
The gene for the ACE2 receptor is also, interestingly, on the 
X chromosome.9 
Gender-specific Factors
Behavioral and cultural variables have also influenced 
current COVID-19 epidemiology. Smoking in particular has 
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What do we already know about this issue?
COVID-19 represents an unparalleled public 
health crisis. Like many other infectious diseases, 
sex and gender differences in health outcomes 
have already been globally observed. 
What was the research question?
We sought to summarize and explain known 
COVID-19-related sex and gender differences.
What was the major finding of the study?
Sex and gender differences are having significant 
impacts on current COVID-19 health outcomes.
How does this improve population health?
This perspective brings attention to the 
importance of sex and gender, specifically as they 
impact current clinical management and research 
during the COVID-19 pandemic.
been implicated as a significant contributor to disease severity, 
and gender-specific patterns are quite apparent here. The 
smoking rate in China is much higher in men than in women 
(288 million men vs 12.6 million women; 2018 data).10 
Likewise, in Italy, men are more likely to smoke than women 
at any age (1.12x to 1.7x, depending on age cohort; 2018 
data).11 Similar gender-specific trends are also present in the 
US, where 17.6% of smokers are men as compared to 13.6% 
of women.12 
In addition, as the traditional caregivers and coordinators 
of care for their loved ones, women, particularly working 
mothers, tend to spend more time than men focused on 
medical issues related to both their own healthcare and that 
of their families.13 In general, men are more likely to engage 
in health-related risks which, even prior to the COVID-19 
pandemic, has been shown to result in higher rates of injury 
and disease.14 Suen et al demonstrated in 2019 that being a 
middle-aged female was a protective factor with regard to 
hand hygiene knowledge and practice.15 
Implications for COVID-19 Management 
As clinical researchers and pharmaceutical companies 
race to find an effective treatment strategy or vaccine for 
COVID-19, no sex- or gender-specific recommendations have 
been released with regard to the care and management of 
individuals affected by the novel coronavirus. Appreciating 
the weight of known sex- and gender-specific epidemiologic 
observations thus far, however, will be an important highlight 
of the information gathered to date. This, combined with what 
is already known about sex- and gender-based pulmonary and 
infectious disease pathology, may lead to important treatment 
breakthroughs that consider the sex and/or gender of patient in 
the comprehensive management plan. 
In addition, the current pandemic weighs heavily on 
emotional wellness along with physical health. COVID-19 
has also released a contagion of fear, anxiety, and stigma that 
will have implications for downstream mental health effects 
including post-traumatic stress disorder (PTSD). In general, 
the prevalence of PTSD has been shown to be substantially 
higher in women.16 This has been re-substantiated in the 
setting of the COVID-19 outbreak in Wuhan, China, where 
women scored significantly higher on the PCL-5 (DSM-5 
self-report measure for PTSD) than men, including higher 
rates of re-experiencing and negative alterations in cognition 
or mood.17 Early recognition and effective treatment can 
ameliorate the burden of PTSD on both the individual and 
society, particularly for women who have been shown to have 
a modest advantage with regard to treatment response.18 
Future Considerations 
Since 2016, the NIH has required inclusion of sex as a 
biological variable (SABV) in the study design for funded 
research.19 Recognizing the weight these variables play in 
disease outcome should result in universal adoption of SABV 
as scientists develop and engage in COVID-19 research. 
While men appear to be disproportionately affected and at risk 
for COVID-19 infection and associated morbidity, researchers 
should avoid the slippery slope of the traditional male-
dominant test and analysis approach. 
When considering pharmaceutical therapy advances, 
several previous studies have established that women are 
much more likely to experience adverse drug reactions 
(ADR) than men.20 In fact, historically the majority of drugs 
recalled from the market were done so due to serious ADRs 
reported by women, quite often because they were never 
tested on women during clinical trials. Several sex-specific 
pharmacokinetic and pharmacodynamic differences have been 
well documented.21 
Yes, time is of the essence right now; however, 
COVID-19 does not get a “pass” in considering sex and 
gender when gathering data or testing treatments. Sex and 
gender have already proven to be crucial variables in the 
short history of COVID-19; they will continue to be factors 
of marked importance. Making healthcare providers and 
researchers aware of their impact in real time will be crucial 
to the integration of susceptibility profiles and improving 
outcomes during an active public health crisis.
Volume 21, no. 3: May 2020 509 Western Journal of Emergency Medicine
Walter et al. Sex- and Gender-Specific Observations and Implications for COVID-19
Address for Correspondence: Lauren A. Walter, MD, University 
of Alabama at Birmingham, Department of Emergency Medicine, 
OHB 251, 619 19th St S, Birmingham, AL 35249. Email: lwalter@
uabmc.edu.
Conflicts of Interest: By the WestJEM article submission agreement, 
all authors are required to disclose all affiliations, funding sources 
and financial or management relationships that could be perceived 
as potential sources of bias. No author has professional or financial 
relationships with any companies that are relevant to this study. 
There are no conflicts of interest or sources of funding to declare.
Copyright: © 2020 Walter et al. This is an open access article 
distributed in accordance with the terms of the Creative Commons 
Attribution (CC BY 4.0) License. See: http://creativecommons.org/
licenses/by/4.0/
REFERENCES
1. Mo P, Xing Y, Xiao Y, et al. Clinical characteristics of refractory 
COVID-19 pneumonia in Wuhan, China. Clin Infect Dis. 2020. In Press.
2. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical 
characteristics of 99 cases of 2019 novel coronavirus pneumonia in 
Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507–13. 
3. Remuzzi A, Remuzzi G. COVID-19 and Italy: what next? Lancet. 
2020;S0140-6736(20)30627-9. 
4. Channappanavar R, Fett C, Mack M, et al. Sex-based differences 
in susceptibility to severe acute respiratory syndrome coronavirus 
infection. J Immunol. 2017;198(10):4046–53. 
5. Matsuyama R, Nishiura H, Kutsuna S, et al. Clinical determinants 
of the severity of Middle East respiratory syndrome (MERS): 
a systematic review and meta-analysis. BMC Public Health. 
2016;16(1):1203. 
6. Sue K. The science behind “man flu.” BMJ. 2017;359:j5560. 
7. Schurz H, Salie M, Tromp G, et al. The X chromosome and sex-
specific effects in infectious disease susceptibility. Hum Genomics. 
2019;13(1):2. 
8. Liu J, Ji H, Zheng W, et al. Sex differences in renal angiotensin 
converting enzyme 2 (ACE2) activity are 17β-oestradiol-dependent 
and sex chromosome-independent. Biol Sex Differ. 2010;1(1):6. 
9. Patel SK, Velkoska E, Freeman M, et al. From gene to protein-
experimental and clinical studies of ACE2 in blood pressure control 
and arterial hypertension. Front Physiol. 2014;5:227. 
10. Cai H. Sex difference and smoking predisposition in patients with 
COVID-19. Lancet Respir Med. 2020. In Press. 
11. Statista Research Department. “Number of Smokers by Age and 
Gender in Italy 2018.” Statista. Available at: www.statista.com/
statistics/501615/italy-smokers-by-age-and-gender/. Accessed March 
27, 2020.
12. National Institute on Drug Abuse. “Are There Gender Differences 
in Tobacco Smoking?” NIDA. Available at: www.drugabuse.gov/
publications/research-reports/tobacco-nicotine-e-cigarettes/are-there-
gender-differences-in-tobacco-smoking. Accessed March 27, 2020.
13. “A Health Care Consumer Gender Gap.” Managed Care Magazine. 
Available at: www.managedcaremag.com/archives/2016/8/health-
care-consumer-gender-gap. Accessed March 27, 2019.
14. Harris CR, Jenkins M. Gender differences in risk assessment: 
Why do women take fewer risks than men? Judgm Decis Mak. 
2006;1(1):48-63.
15. Suen LKP, So ZYY, Yeung SKW, et al. Epidemiological investigation 
on hand hygiene knowledge and behaviour: a cross-sectional study 
on gender disparity. BMC Public Health. 2019;19(1):401. 
16. K Farhood L, Fares S, Hamady C. PTSD and gender: Could gender 
differences in war trauma types, symptom clusters and risk factors 
predict gender differences in PTSD prevalence? Arch Womens Ment 
Health. 2018;21(6):725–33. 
17. Liu N, Zhang F, Wei C. Prevalence and predictors of PTSS during 
COVID-19 Outbreak in China Hardest-hit Areas: Gender differences 
matter. Psychiatry Res. 2020. In Press.
18. Blain LM, Galovksi TE, Robinson T. Gender differences in recovery 
from posttraumatic stress disorder: a critical review. Aggress Violent 
Behav. 2010;15(6):463-74. 
19. “NIH Policy on Sex as a Biological Variable.” National Institutes of 
Health, U.S. Department of Health and Human Services. Available 
at: orwh.od.nih.gov/sex-gender/nih-policy-sex-biological-variable. 
Accessed March 27th, 2020.
20. Tran C, Knowles SR, Liu BA, et al. Gender differences in adverse 
drug reactions. J Clin Pharmacol. 1998;38(11):1003–9. 
21. Franconi F, Campesi I. Pharmacogenomics, pharmacokinetics and 
pharmacodynamics: interaction with biological differences between 
men and women. Br J Pharmacol. 2014;171(3):580–94. 
